Zhejiang Huahai Pharmaceutical (600521.SH) has obtained a drug registration certificate.

16:19 24/02/2026

Huahai Pharmaceuticals (600521.SH) announcement: The company has recently received the "Drug Registration Certificate" for the approval and issuance of malic acid nizatidine tablets from the National Medical Products Administration. Malic acid nizatidine tablets are used to improve symptoms such as loss of appetite, nausea, vomiting, belching, abdominal distention, borborygmus, abdominal pain, diarrhea, and constipation caused by gastrointestinal motility disorders and irritable bowel syndrome.

Zhejiang Huahai Pharmaceutical (600521.SH) announced that the company has recently received the "Drug Registration Certificate" for malic acid peramivir tablets issued by the National Medical Products Administration. Malic acid peramivir tablets are used to improve symptoms such as loss of appetite, nausea, vomiting, belching, abdominal distension, abdominal rumbling, abdominal pain, diarrhea, and constipation caused by disorders of gastrointestinal motility and irritable bowel syndrome.

On February 24th, XD INC (02400) spent 4.9054 million Hong Kong dollars to repurchase 65,000 shares.

Huiyu Pharmaceutical (688553.SH) passed the on-site inspection by the U.S. FDA.

On February 24, Taiwan (09890) spent HK$14.757 million to repurchase 750,000 shares.

On February 24th, XD INC (02400) spent 4.9054 million Hong Kong dollars to repurchase 65,000 shares.

Huiyu Pharmaceutical (688553.SH) passed the on-site inspection by the U.S. FDA.

On February 24, Taiwan (09890) spent HK$14.757 million to repurchase 750,000 shares.